ProteinSimple has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on listing the stock on the NASDAQ under the ticker symbol “PRTN.” JP Morgan and BofA Merill Lynch will serve as lead underwriters. Based in Santa Clara, Calif., ProteinSimple is a provider of protein analysis. Its backers include Essex Woodlands Health Ventures, Novo AS and Domain Associates.
SANTA CLARA, Calif., May 1, 2014 /PRNewswire/ — ProteinSimple announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by ProteinSimple. The number of shares to be offered and the price range for the offering have not yet been determined. ProteinSimple has applied for a listing of its common stock on The NASDAQ Global Stock Market under the symbol “PRTN”.
J.P. Morgan and BofA Merrill Lynch will act as joint book-running managers for the offering. Cowen and Company and Leerink Partners will act as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the offering, when available, may be obtained from either: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by email at [email protected] .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Our goal is simply to help researchers gain a better understanding of proteins and their role in disease. We develop and commercialize proprietary systems and consumables for protein analysis that ultimately help reveal new insights into the true nature of proteins. Our goal is to make protein analysis simpler, more quantitative and affordable. Our comprehensive portfolio of tools includes Simple Western systems that quantify protein expression and Biologics systems that probe the structure and purity of protein-based therapeutics. We have over 200 employees, more than 14,000 systems installed around the world, and our headquarters is in Santa Clara, California
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.